Seeking Alpha

Seeking Alpha Portfolio App for iPad

26,309 people get JNJ articles and Market Currents by email alert.

Get email alerts on JNJ »

JNJ

Johnson & Johnson

5/21/2013, 6:52 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 11:39 AM Johnson & Johnson's (JNJ -0.2%) says Simponi, its drug for hard to treat ulcerative colitis being produced by subsidiary Janssen Biotech, has received FDA approval. The injectable drug is used to induce and maintain remission from the chronic inflammatory bowel disease, which is marked by inflammation and ulceration of the innermost lining of the colon. Comment! [Healthcare]
Monday, May 13, 1:10 PM Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform and raises its price target to $100 from $70. The firm cites optimism over a number of upcoming catalysts for its leukemia drug Ibrutnib, which is being jointly developed by PCYC and JNJ's Janssen Pharmaceuticals. 1 Comment [Healthcare, On the Move]
Thursday, May 9, 5:29 PM A $2.2B settlement of a federal investigation into Johnson & Johnson (JNJ) sales practices is on hold, WSJ reports, as JNJ seeks to avoid wording in the agreement that could leave it vulnerable to private lawsuits. JNJ had agreed to settle a Justice Department investigation into allegations it had illegally promoted drugs including the antipsychotic Risperdal. Comment! [Consumer]
Monday, May 6, 12:56 PM Johnson & Johnson (JNJ -1%) dips today on the back of its announcement over the weekend that it's recalling all bottles of Children's Tylenol it made and sold in South Korea, after finding high levels of acetaminophen, it's main ingredient. The company says it traced the problem to the failure of machines that fill the bottles at the end of manufacturing runs. Once they failed, some of the remaining bottles were filled by hand, leading to the improper concentrations. JNJ says the health risk is remote, and it hasn't received any reports of harm. The recall doesn't affect any products sold in the U.S. 1 Comment [Healthcare, Global & FX]
Friday, April 26, 3:42 PM Looking for dividend picks, Marketwatch screens the S&P 1,500 for 1) Stock trades at less than a 17x PE 2) Dividend yield 20% or more higher than S&P 500 3) Raised dividend at least 5 times in last 5 years 4) S&P Quality Rank of B+ or better. The winners: T, AVA, BAX, CAH, CAG, ED, JNJ, LG, TAP, RAI, SCG, UVV, WR, XEL. 1 Comment
Thursday, April 25, 1:59 PM Johnson & Johnson (JNJ) declares $0.66/share quarterly dividend, 8.2% increase from prior dividend of $0.61. Forward yield 3.10%. For shareholders of record May 28. Payable June 11. Ex-div date May 23. (PR) 4 Comments [Dividends]
Thursday, April 18, 10:00 AM Johnson & Johnson (JNJ) will realize an after-tax gain of $213M from the sale of 82M ADSs in Elan back to the Irish company. J&J had tendered 107.4M shares in Elan's repurchase program . (PR) Comment! [Healthcare]
Thursday, April 18, 9:40 AM Johnson & Johnson (JNJ) tenders 107.4M Elan (ELN) shares at the strike price of $11.25 in the latter's $1B stock buyback. The total number of shares tendered is 239.7M, of which Elan plans to purchase 76%. Elan is retiring 14.8% of the stock in issue as part of the repurchase plan. (PR) Comment! [Healthcare]
Wednesday, April 17, 3:09 AM Johnson & Johnson (JNJ) has won the second lawsuit over its ASR hip implant, with a jury in Chicago ruling that the company didn't inappropriately market the all-metal device, which the plaintiff argued J&J knew was flawed. The verdict follows a decision in LA to award $8.3M against the company. J&J faces 10,000 lawsuits over ARS, including a class-action case in Ohio. Comment! [Healthcare]
Tuesday, April 16, 7:52 AM Johnson & Johnson (JNJ): Q1 EPS of $1.44 beats by $0.04. Revenue of $17.5B (+8.5% Y/Y) beats by $0.04B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 16, 12:05 AM Notable earnings before Tuesday’s open: AMTD, BLK, CMA, GS, GWW, JNJ, KO, NTRS, USB, WWW Comment! [Earnings]
Monday, April 15, 5:30 PM Notable earnings before Tuesday’s open: AMTD, BLK, CMA, GS, GWW, JNJ, KO, NTRS, USB, WWW Comment! [Earnings]
Thursday, April 11, 10:29 AM Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III clinical trial using Ibrutinib versus Chlorambucil to treat chronic lymphocytic leukemia and small lymphocyctic lymphoma has enrolled its fifth patient. The enrollment subsequently triggers a fourth $50M milestone payment obligation from JNJ's Janssen Biotech, who is collaborating with PCYC on Ibrutinib in oncology. On Monday, the drug was granted a 3rd "Breakthrough Therapy Designation" by the FDA. 1 Comment [Healthcare, On the Move]
Wednesday, April 10, 1:37 PM Jefferies raises its price targets on big pharma names Pfizer (PFE +2.6%) ($33), Merck (MRK +2.7%) ($48), Johnson & Johnson (JNJ +0.7%) ($85), Eli Lilly (LLY +1.4%) ($44), Bristol-Myers Squibb (BMY +0.5%) ($45), AbbVie (ABBV +1.2%) ($50), and Abbot Laboratories (ABT +1.1%) ($42). "We remain positive on pharmaceuticals," Jefferies says, "valuation is attractive for most stocks." 6 Comments [Healthcare]
Monday, April 8, 1:02 PM Johnson & Johnson's (JNJ -1.6%) slips today on a downgrade to Neutral at JPMorgan, saying the stock has reached a "trading premium." Last June, JP notes, the stock was trading at a 5% discount to the "sum-of-its-parts." Now, after a 30% run, the shares trade at an 8% premium, and despite an improvement in the fundamentals, the stock is poised to plateau, at least over the near term. The firm did however, ratchet-up its price target to $83 from $77. Comment! [Healthcare, On the Move]
Thursday, April 4, 4:25 PM Johnson and Johnson (JNJ) subsidiary Cordis Corp notches a legal victory as the U.S. Court of Appeals for the Federal Circuit overturns a ruling ordering a payment of $482M to radiologist Bruce Saffran. Saffran alleges patent infringement in connection with Cordis' Cypher stents. Comment! [Healthcare]

1
2
3
4
5
6
...
30
Next Page